Activity
Connections
RFK Jr. Continues to Influence U.S. Health Policy Amid Controversies
RFK Jr., head of the Department of Health and Human Services, continues to push controversial policies, including significant budget cuts and vaccine policy meddling, amid widespread criticism. His actions threaten to reshape U.S. public health infrastructure and policy debates moving forward.
FDA Approves Otarmeni, First Dual-AAV Gene Therapy for Severe Hearing Loss
The FDA has approved Otarmeni, a pioneering gene therapy for severe hearing loss caused by OTOF gene mutations. This landmark approval could transform treatment options and improve quality of life for affected individuals.
Trump Signs Executive Order to Fast-Track Psychedelic Drug Research and Access
President Donald Trump recently signed an executive order to accelerate the approval process for psychedelic therapies, including psilocybin and ibogaine. The move is expected to boost research and commercialization, impacting mental health treatment options.
FDA approves 7.2 mg Wegovy boosting weight loss 21%; Indian generics cut prices to $14/month
The FDA approved a triple-strength 7.2 mg dose of Wegovy, enabling patients to lose 21% body weight on average. Simultaneously, Indian companies launched significantly cheaper generic versions of semaglutide drugs, broadening global access and upping market competition.
FDA Faces Leadership Shakeup as Vaccine Chief and Top Official Depart
Two key departures from the FDA suggest leadership instability amid ongoing vaccination debates. The ousting of the vaccine chief and Vinay Prasad's resignation may impact future health policies and vaccine regulation.
FDA Reverses Decision on Rare Blood Cancer Drug, Cigna Expands with CarepathRx Acquisition
FDA reverses its initial approval of a rare blood cancer drug, raising concerns about regulatory stability. Separately, Cigna acquires CarepathRx to deepen its presence in hospital pharmacy services, marking a significant expansion.
FDA Announces Regulations for Custom Gene Therapies Amid Rare Disease Drug Debate
The FDA has set new regulations for personalized gene therapies, potentially boosting innovation in rare disease treatments. Concurrently, the agency faces criticism from advocates over its approval decisions, reflecting a challenging regulatory landscape.
FDA Pushes for Over-the-Counter Access Amid Industry Resistance to GLP-1 Drugs
The FDA is pushing for over-the-counter access to medications like GLP-1 drugs, sparking debate over safety, profits, and public health. Industry resistance and regulatory challenges complicate this push.